RNS Number : 0770G
Eco Animal Health Group PLC
27 September 2024
 

27 September 2024

 

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Result of Annual General Meeting

  

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at its Annual General Meeting held yesterday all resolutions proposed to the meeting were duly passed.

Votes received in relation to each resolution were as follows:

Resolution

For

 

%

 

Discretionary

 

%

Against

 

%

01

41,070,268

100.00

Nil

0.00

Nil

0.000

02

36,456,852

88.768

Nil

0.00

4,613,165

11.232

03

40,961,390

99.735

Nil

0.00

108,878

0.265

04

34,395,129

84.081

Nil

0.00

6,511,866*

15.919

05

41,070,404

99.999

Nil

0.00

541

0.001

06

40,976,766

99.771

Nil

0.00

94,179

0.229

07

40,945,821

99.709

784

0.002

118,663

0.289

08

40,957,821

99.726

784

0.002

111,663

0.272

09

41,046,763

99.941

7,500

0.018

16,682

0.041

 

* Note: The Board has been informed that a shareholder holding a block of 1,902,729 votes incorrectly lodged a proxy in respect of these shares against resolution 4.  This shareholder acknowledged that  the intent had been to vote these shares in favour of resolution 4.

-Ends-

For further information please contact:

 

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)


020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

 


About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSEUFDWELSEFU
Eco Animal Health (LSE:EAH)
過去 株価チャート
から 11 2024 まで 12 2024 Eco Animal Healthのチャートをもっと見るにはこちらをクリック
Eco Animal Health (LSE:EAH)
過去 株価チャート
から 12 2023 まで 12 2024 Eco Animal Healthのチャートをもっと見るにはこちらをクリック